

Annual Meeting of Stockholders

Minnesota, United States and Melbourne, Australia – 1 February 2022- Osprey Medical Inc. (ASX:OSP) (**Osprey or the Company**) advises that its Annual Meeting of stockholders will be held as a virtual meeting on Thursday, 2 June 2022 at 10.00am Australian Eastern Standard Time (Wednesday, 1 June 2022 at 7.00pm U.S. Central Time). The closing date for the receipt of nominations from persons wishing to be considered for election as a director is 10 February 2022 Australian time (9 February 2022 U.S. time).

Details regarding the 2022 Annual Meeting will be provided in a separate Notice of Meeting which will be provided to securityholders closer to the date of the meeting and will also be available on the ASX Market Announcements Platform and the Company's website (www.ospreymed.com). The Notice of Meeting will provide details on how to view and listen to the meeting presentations, vote online and submit questions in real-time.

This release has been authorised for lodgement to ASX by Mike McCormick, CEO of Osprey Medical.

– ENDS –

Contact details:

Osprey Medical

Doug Schoenberg
VP of Marketing
T: +1 (952) 955 8230
dschoenberg@ospreymed.com

Investors

Prash Jitendran
Vesparum Capital
T: +61 3 8582 4800
ospreymed@vesparum.com

Media Relations

Ciara Byrne
Mana Communications
T: +61 41 3519 430
cbyrne@manacommunications.com

About Osprey Medical (ASX: OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Foreign Ownership Restriction

Osprey's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.